D.E. Shaw & Co’s Novartis NVS Stock Holding History

D.E. Shaw & Co’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.16M	Sell	40,300 -29,300	-42%	-$4.49M	﹤0.01%	2032
2025 Q4	$9.6M	Buy	+69,600	New	+$9.11M	0.01%	1790
2023 Q4	–	Sell	-11,500	Closed	-$1.17M	–	4507
2023 Q3	$1.17M	Buy	+11,500	New	+$1.17M	﹤0.01%	2967
2023 Q1	–	Sell	-3,000	Closed	-$272K	–	4732
2022 Q4	$272K	Buy	+3,000	New	+$253K	﹤0.01%	4130
2021 Q1	–	Sell	-38,900	Closed	-$3.67M	–	4350
2020 Q4	$3.67M	Hold	38,900	–	–	﹤0.01%	2110
2020 Q3	$3.38M	Hold	38,900	–	–	﹤0.01%	1981
2020 Q2	$3.4M	Hold	38,900	–	–	﹤0.01%	1976
2020 Q1	$3.21M	Hold	38,900	–	–	0.01%	1803
2019 Q4	$3.68M	Hold	38,900	–	–	﹤0.01%	1987
2019 Q3	$3.38M	Buy	+38,900	New	+$3.49M	﹤0.01%	1949
2015 Q1	–	Sell	-53,680	Closed	-$4.46M	–	3888
2014 Q4	$4.46M	Hold	53,680	–	–	0.01%	1664
2014 Q3	$4.53M	Hold	53,680	–	–	0.01%	1636
2014 Q2	$4.35M	Buy	53,680 +35,712	+199%	+$2.81M	0.01%	1725
2014 Q1	$1.37M	Sell	17,968 -42,408	-70%	-$3.09M	﹤0.01%	2759
2013 Q4	$4.35M	Hold	60,376	–	–	0.01%	1797
2013 Q3	$4.15M	Sell	60,376 -7,588	-11%	-$502K	0.01%	1772
2013 Q2	$4.31M	Buy	+67,964	New	+$4.42M	0.01%	1466

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's NVS Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Novartis (NVS) in Q1 2026, closing a stake of 8,000 shares — an estimated $1.23M sold.

D.E. Shaw & Co first reported a position in NVS in Q2 2013 and held it in 41 quarters. The position peaked at $159M in Q4 2021. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

D.E. Shaw & Co reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
D.E. Shaw & Co sold 8,000 Novartis shares in Q1 2026, an estimated $1.23M.
D.E. Shaw & Co first reported a position in Novartis in Q2 2013 and held it in 41 quarters.
D.E. Shaw & Co's Novartis position peaked at $159M in Q4 2021.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.